NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced a collaboration to validate the Centre of Excellence for the Prevention of Organ Failure's (PROOF Centre) assay for organ rejection in heart transplant patients.

HTG will use the HTG Edge System in the clinical laboratory of St. Paul's Hospital, Providence Health Care in Vancouver, British Columbia to start clinical validation of the PROOF Centre's molecular biomarker test, which is intended to help physicians better monitor and treat patients after a heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.